COMPLETE: International Acute Ischemic Stroke Registry With the Penumbra System Aspiration Including the 3D Revascularization Device



Status:Recruiting
Conditions:Peripheral Vascular Disease, Neurology
Therapuetic Areas:Cardiology / Vascular Diseases, Neurology
Healthy:No
Age Range:18 - Any
Updated:9/7/2018
Start Date:July 2, 2018
End Date:December 2021
Contact:Daniel Choi
Email:dchoi@penumbrainc.com
Phone:510.995.9792

Use our guide to learn which trials are right for you!

The purpose of this study is to collect real-world performance and safety data on the
Penumbra System including the 3D Revascularization Device in patients with acute ischemic
stroke (AIS) due to blockages of the large blood vessels in the brain.

Registry Objective: The primary objective of this registry is to collect data on Penumbra
System including the 3D Revascularization Device in a patient population with acute ischemic
stroke (AIS) secondary to intracranial large vessel occlusion (LVO).

Registry Design: This will be a prospective, single-arm, multi-center observational registry
and will include patients that present with either anterior or posterior LVO who are eligible
for mechanical thrombectomy using the Penumbra System.

Registry Duration: Subjects will be in the registry for approximately 90 days from enrollment
to last follow-up.

Data Management: Electronic Case Report Forms (eCRFs) will be used at all investigational
sites. All registry data will be entered into commercially available web-based electronic
data capture system (EDC). Data entry will be performed by the study site personnel.
Automated data quality checks will display warnings for invalid data. Additionally, manual
review of data listings may be used to identify data discrepancies or inconsistencies.

Inclusion Criteria:

- Patient age ≥ 18

- Pre-stroke mRS 0-1

- Patient experiencing acute ischemic stroke secondary to intracranial large vessel
occlusion who are eligible for mechanical thrombectomy using the Penumbra System

- Planned frontline treatment with Penumbra System

- Signed informed consent per Institution Review Board/Ethics Committee

Exclusion Criteria:

- Any comorbid disease or condition expected to compromise survival or ability to
complete follow-up assessments through 90 days.

- Currently participating in an investigational (drug, device, etc) clinical trial that
will confound study endpoints. Patients in observational, natural history, and/or
epidemiological studies not involving intervention are eligible.
We found this trial at
3
sites
?
mi
from
Toledo, OH
Click here to add this to my saved trials
Harlingen, Texas 78550
?
mi
from
Harlingen, TX
Click here to add this to my saved trials
New York, New York 10029
?
mi
from
New York, NY
Click here to add this to my saved trials